Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma

PDF  |  How to cite

Oncotarget. 2023; 14:836-836. https://doi.org/10.18632/oncotarget.28496

Metrics: PDF 217 views  |   ?  

Michèle Welti1,2, Phil F. Cheng1,2, Joanna Mangana1,2, Mitchell P. Levesque1,2, Reinhard Dummer1,2 and Laurence Imhof1,2,3

1Department of Dermatology, University Hospital Zurich (USZ), Zurich 8091, Switzerland
2Faculty of Medicine, University of Zurich (UZH), Zurich 8032, Switzerland
3Institute for Biomedical Engineering, ETH Zurich, Zurich 8092, Switzerland

Published: September 25, 2023

Copyright: © 2023 Welti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: The melanoma registry database of the Department of Dermatology has been partially supported by an unrestricted grant to the University of Zurich from Amgen, Novartis, BMS, MSD and Pierre Fabre. The study itself required no external funding.

Original article: Oncotarget. 2022; 13:1370-1379. DOI: https://doi.org/10.18632/oncotarget.28333.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28496